Suzhou Lixin Pharmaceutical Co., Ltd, established in 2000, is a manufacturer of active pharmaceutical ingredients operating GMP facilities in Suzhou, Jiangsu and Zibo, Shandong, with a product range covering oncology, cardiovascular, and antiviral APIs including Semaglutide, Tenofovir Alafenamide Fumarate, Esomeprazole, Bortezomib, Oxaliplatin, Capecitabine, Ticagrelor, Clopidogrel Bisulfate, and Gefitinib, among many other intermediates and chiral building blocks. The company has built its regulatory track record over more than two decades: it obtained its first new drug certificate in 2009, passed a US FDA on-site inspection in 2010, secured its first CEP in 2012, passed EMA/EDQM inspection in 2016, and stood up a second GMP site in Shandong in 2017 that earned its own CEP in 2022. It holds dozens of patents, including international PCT filings across the US, Europe, and China, and offers CRO, CMO, and CDMO contract services backed by dedicated production lines, tight control from starting materials through to finished product, and an experienced regulatory, patent, and sales team serving customers across North America, Western and Eastern Europe, and Asia.
No comments available.
Leave your rating & comment